Aspen Technology to Present at the Nasdaq 35th Investor Program
Get Alerts AZPN Hot Sheet
Join SI Premium – FREE
BEDFORD, Mass.--(BUSINESS WIRE)-- Aspen Technology, Inc. (NASDAQ: AZPN), a leading provider of software and services to the process industries, today announced that Antonio Pietri, President and Chief Executive Officer, will present at the Nasdaq 35th Investor Program being held in association with Morgan Stanley at The May Fair Hotel in London on Tuesday, November 29, 2016 at 12:00 p.m. Greenwich Mean Time.
The presentation will be webcast live and available for a limited time on the Investor Relations section of the company’s website at www.aspentech.com.
About AspenTechAspenTech is a leading supplier of software that optimizes process manufacturing – for energy, chemicals, engineering and construction, and other industries that manufacture and produce products from a chemical process. With integrated aspenONE solutions, process manufacturers can implement best practices for optimizing their engineering, manufacturing and supply chain operations. As a result, AspenTech customers are better able to increase capacity, improve margins, reduce costs and become more energy efficient. To see how the world’s leading process manufacturers rely on AspenTech to achieve their operational excellence goals, visit www.aspentech.com.
© 2016 Aspen Technology, Inc. AspenTech, aspenONE and the Aspen leaf logo are registered trademarks of Aspen Technology, Inc. All rights reserved. All other trademarks are property of their respective owners.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161122005742/en/
Media Contact
AspenTech
David Grip, +1 781-221-5273
[email protected]
or
Investor
Contact
ICR
Brian Denyeau, +1 646-277-1251
[email protected]
Source: Aspen Technology, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OKX Card Usage Surges Across Europe as Crypto Moves Into Everyday Spending
- BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
- INTURAI VENTURES ENTERS INTO DEFINITIVE AGREEMENT FOR DOMECOMMAND ACQUISITION AND FILES AMENDED OFFERING DOCUMENT
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share